CP
CASC

Corbenic Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Corbenic Partners’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-33
Closed – – 276
2017
Q2 		$0 Hold
33
– – ﹤0.01% 211
2017
Q1 		$0 Hold
33
– – ﹤0.01% 228
2016
Q4 		$0 Hold
33
– – ﹤0.01% 223
2016
Q3 		$0 Hold
33
– – ﹤0.01% 233
2016
Q2 		$0 Hold
33
– – ﹤0.01% 197
2016
Q1 		$0 Hold
33
– – ﹤0.01% 201
2015
Q4 		$0 Hold
33
– – ﹤0.01% 212
2015
Q3 		$1K Hold
33
– – ﹤0.01% 162
2015
Q2 		$1K Hold
33
– – ﹤0.01% 143
2015
Q1 		$0 Sell
33
-14
-30% -$137 ﹤0.01% 231
2014
Q4 		$1K Buy
47
+14
+42% +$152 ﹤0.01% 221
2014
Q3 		$0 Hold
33
– – ﹤0.01% 142
2014
Q2 		$1K Hold
33
– – ﹤0.01% 107
2014
Q1 		$1K Hold
33
– – ﹤0.01% 107
2013
Q4 		$0 Hold
33
– – ﹤0.01% 122
2013
Q3 		$0 Hold
33
– – ﹤0.01% 129
2013
Q2 		$0 Buy
+33
New +$424 ﹤0.01% 114

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Corbenic Partners's CASC Position: Q3 2017 in Review

Corbenic Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 33 shares.

Corbenic Partners first reported a position in CASC in Q2 2013 and held it in 17 quarters. The position peaked at $1K in Q3 2015. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • Corbenic Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Corbenic Partners sold 33 Cascadian Therapeutics, Inc. shares in Q3 2017.
  • Corbenic Partners first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 17 quarters.
  • Corbenic Partners's Cascadian Therapeutics, Inc. position peaked at $1K in Q3 2015.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on Corbenic Partners's 13F filing for Q3 2017, filed 26 Oct 2017.